Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIO
BuyPremium GrowerBio-Rad Laboratories, Inc. · Healthcare · United States · $10.4B · Avg Vol: $95M/d
COMPANY DESCRIPTION
Bio-Rad Laboratories, Inc. develops, manufactures, and markets a comprehensive range of innovative instruments, reagents, and software for both life science research and clinical diagnostic markets worldwide. The company's competitive moat is established through its diverse portfolio of proprietary technologies, robust R&D pipeline, and a significant installed base of instruments that generate recurring revenue from consumables. Bio-Rad is a global leader in scientific instrumentation, recognized for its broad product catalog and scientific expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.8B | 2.7B | 2.6B | 2.6B | -2.7% | 2.6B | 2.6B | 2.6B | 1.0% |
| EPS | -121.79 | -21.82 | -65.36 | 27.87 | — | 8.22 | 26.64 | 28.18 | 0.5% |
| Shares | 29.6M | 28.5M | 28.0M | 27.0M | -8.8% | 21.7M | — | — | — |
| Debt | 1.4B | 1.4B | 1.4B | 1.4B | -0.0% | 1.4B | — | — | — |
| Equity | 9.6B | 8.7B | 6.6B | 7.5B | -8.1% | — | — | — | — |
| Op CF | 194.4M | 374.9M | 455.2M | 532.2M | 39.9% | 492.6M | — | — | — |
| Inv CF | -1.2B | 20.2M | -160.2M | -189.7M | — | — | — | — | — |
| Fin CF | 973.6M | -425.6M | -218.8M | -283.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIO | Bio-Rad Laboratories, Inc.(you) | $10.4B | 70 | Buy |
| ITGR | Integer Holdings Corporation | $4.3B | 68 | Buy |
| STE | STERIS plc | $22.8B | 76 | Buy |
| PODD | Insulet Corporation | $10.1B | 48 | Hold |
| GMED | Globus Medical, Inc. | $11.1B | 92 | Strong Buy |
| PEN | Penumbra, Inc. | $12.7B | 51 | Hold |
| GKOS | Glaukos Corporation | $10.6B | 46 | Hold |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| BRKR | Bruker Corporation | $8.7B | 47 | Hold |
| GEHC | GE HealthCare Technologies Inc. | $32.4B | 63 | Hold |
Peer medians: ROE -30.9% · P/E 26.8x · Gross margin 58.3%